These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 14693566)

  • 1. In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.
    Yong D; Yum JH; Lee K; Chong Y; Choi SH; Rhee JK
    Antimicrob Agents Chemother; 2004 Jan; 48(1):352-7. PubMed ID: 14693566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Gunderson BW; Ibrahim KH; Peloquin CA; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 2003 Jan; 47(1):398-9. PubMed ID: 12499223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
    Sweeney MT; Zurenko GE
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
    Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
    J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
    Rybak MJ; Cappelletty DM; Moldovan T; Aeschlimann JR; Kaatz GW
    Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy.
    Stefani S; Mezzatesta ML; Tempera G; Debbra E; Schito AM; Nicoletti G; Marchére A
    Clin Microbiol Infect; 2002 Jun; 8(6):368-72. PubMed ID: 12084106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.
    Livermore DM; Warner M; Mushtaq S; North S; Woodford N
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1112-4. PubMed ID: 17210773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea.
    Yum JH; Choi SH; Yong D; Chong Y; Im WB; Rhee DK; Lee K
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5381-6. PubMed ID: 20837761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid.
    Howe RA; Wootton M; Noel AR; Bowker KE; Walsh TR; MacGowan AP
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3651-2. PubMed ID: 14576139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of linezolid resistance in Enterococcus faecium not dependent on linezolid treatment.
    Bonora MG; Ligozzi M; Luzzani A; Solbiati M; Stepan E; Fontana R
    Eur J Clin Microbiol Infect Dis; 2006 Mar; 25(3):197-8. PubMed ID: 16498524
    [No Abstract]   [Full Text] [Related]  

  • 12. [In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains].
    Efe S; Sinirtaş M; Ozakin C
    Mikrobiyol Bul; 2009 Oct; 43(4):639-43. PubMed ID: 20084917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro activity of linezolid/ertapenem combination in resistant gram-positive bacteria].
    Eraç B; Taşli H; Ermertcan S; Cilli F; Limoncu MH
    Mikrobiyol Bul; 2009 Jan; 43(1):45-51. PubMed ID: 19334379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria.
    Munckhof WJ; Giles C; Turnidge JD
    J Antimicrob Chemother; 2001 Jun; 47(6):879-83. PubMed ID: 11389123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents.
    Takhi M; Singh G; Murugan C; Thaplyyal N; Maitra S; Bhaskarreddy KM; Amarnath PV; Mallik A; Harisudan T; Trivedi RK; Sreenivas K; Selvakumar N; Iqbal J
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5150-5. PubMed ID: 18768315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid-resistant Enterococcus faecium and Enterococcus faecalis isolated from a septic patient: report of first isolates in Germany.
    Halle E; Padberg J; Rosseau S; Klare I; Werner G; Witte W
    Infection; 2004 Jun; 32(3):182-3. PubMed ID: 15188081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria.
    Ueda Y; Sunagawa M
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2471-80. PubMed ID: 12878507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
    Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
    Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
    Drago L; Nicola L; De Vecchi E
    Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
    Tünger A; Aydemir S; Uluer S; Cilli F
    Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.